Skip to main content

New research
Research history
Search
Cases
Professionals
Blog
Pricing
Docs

Sign in Start free

Codiak BioSciences, Inc. Bankruptcy Case

C

Codiak BioSciences, Inc.

Sale Process

Case No.: 23-10350 · Delaware · Petition date: Mar 27, 2023

Research this case Track this case Sign in

OverviewHearings Professionals

Key professionals

Bankruptcy Counsel

Young Conaway Stargatt & Taylor, LLP

Chief Restructuring Officer

Province, LLC

Claims and Noticing Agent

Stretto, Inc.

Real Estate Professional

Colliers International New England LLC

Judge: Mary F. Walrath
Petition assets: $100M–$500M
Petition liabilities: $50M–$100M
Industry: Healthcare
Debtors: 2

Codiak BioSciences, Inc. is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company specializing in exosome-based therapeutics. Founded in 2015, the company utilizes its proprietary engEx Platform to engineer exosomes for treating oncology, infectious, and rare diseases. Its pipeline includes candidates such as exoSTING, exoIL-12, and exoASO-STAT6. Codiak maintains a strategic manufacturing partnership with Lonza Rockland, Inc. and has historically raised $394.9 million in capital. The company is publicly traded on the NASDAQ under the ticker symbol CDAK.

Case background, summaries, and key terms are generated from the filings on this docket. Docket entries and documents come from the court.

Report a data error